Tyrosine kinase inhibitorFDA-approvedSecond-line
Bosutinib
How it works
Blocks the BCR-ABL tyrosine kinase enzyme, which is overactive in CML cells, and also inhibits other tyrosine kinases involved in cancer growth.
Cancer types
Leukemia— BCR-ABL-positive
Efficacy
In clinical trials, around 60% of BCR-ABL-positive patients achieved a major cytogenetic response, with a median progression-free survival of approximately 2 years.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Researchers Identify Potential Way to Overcome Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Lower Initial Dose of Bosutinib May Reduce Treatment Discontinuation in CML Patients | Leukemia | phase-2 | The rate of bosutinib discontinuation due to drug-related toxicities was significantly lower, at 11.4% vs. 28.2% (p = 0.015). | Source → |
| Managing Side Effects of Bosutinib for Chronic Myeloid Leukemia | Leukemia | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.